Patent Ductus Arteriosus - Pipeline Review, H1 2012

Global Markets Direct, June 2012, Pages: 32

Patent Ductus Arteriosus – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Patent Ductus Arteriosus - Pipeline Review, H1 2012', provides an overview of the Patent Ductus Arteriosus therapeutic pipeline. This report provides information on the therapeutic development for Patent Ductus Arteriosus, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Patent Ductus Arteriosus. 'Patent Ductus Arteriosus - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Patent Ductus Arteriosus.
- A review of the Patent Ductus Arteriosus products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Patent Ductus Arteriosus pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Patent Ductus Arteriosus.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Patent Ductus Arteriosus pipeline depth and focus of Patent Ductus Arteriosus therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Patent Ductus Arteriosus Therapeutic Products under Development, Key Players in Patent Ductus Arteriosus Therapeutics, Patent Ductus Arteriosus Pipeline Overview, Patent Ductus Arteriosus Pipeline, Patent Ductus Arteriosus Pipeline Assessment

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Patent Ductus Arteriosus Overview
Therapeutics Development
An Overview of Pipeline Products for Patent Ductus Arteriosus
Patent Ductus Arteriosus Therapeutics under Development by Companies
Patent Ductus Arteriosus Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Patent Ductus Arteriosus Therapeutics – Products under Development by Companies
Patent Ductus Arteriosus Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Patent Ductus Arteriosus Therapeutics Development
PLx Pharma Inc.
Patent Ductus Arteriosus – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
PL 4500 Indomethacin-PC - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Indomethacin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ibuprofen - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ibuprofen - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Paracetamol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Patent Ductus Arteriosus Therapeutics - Dormant Products
Patent Ductus Arteriosus – Product Development Milestones
Featured News & Press Releases
Mar 28, 2012: PLx Pharma Receives $565,449 Grant For Research On Congenital Heart Defect In Premature Babies
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Patent Ductus Arteriosus, H1 2012
Products under Development for Patent Ductus Arteriosus – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Investigation by Universities/Institutes, H1 2012
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Comparative Analysis by Pre-Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
PLx Pharma Inc., H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Patent Ductus Arteriosus Therapeutics – Dormant Products

List of Figures
Number of Products under Development for Patent Ductus Arteriosus, H1 2012
Products under Development for Patent Ductus Arteriosus – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Early Clinical Stage Products, H1 2012
Pre-Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012

Customers who bought this item also bought

• Alzheimer's Disease – Pipeline Review, H1 2013
• Rhinitis - Pipeline Review, H1 2013
• Bronchiectasis - Pipeline Review, H1 2013
• Secondary Hyperparathyroidism - Pipeline Review, H1 2013
• Scar - Pipeline Review, H1 2013
• Inflammatory Bowel Disease - Pipeline Review, H1 2013
• Osteoporosis - Pipeline Review, H1 2013
• Burns - Pipeline Review, H1 2013
• Eczema - Pipeline Review, H1 2013
• Liver Transplantation – Pipeline Review, H1 2013